ERBB2 and gastric cancer: While originally known for its effects in breast cancer, HER2 overexpression has been shown to result in worse prognosis in gastric cancer [29, 30] although there are conflicting studies which suggest that it has no effect or is even beneficial in terms of prognosis [31, 32].